Ending the reign of short-acting β2-agonists in Australia?

David Price, Christine Jenkins, Kerry Hancock, Rebecca Vella, Florian Heraud, Porsche Le Cheng, Ruth B Murray, Sinthia Bosnic-Anticevich, Fabio Botini,, Victoria Carter, Angelina Catanzariti, Joe Doan, Ata Kichkin, Thao Le, Chantal E. Le Lievre, Chi Ming Lau, Dominique Novic, John Pakos, Kanchanamala Ranasinghe, Alex RoussosJosephine Samuel-King, Anita Sharma, Bruce Willet, Eric D Bateman

Research output: Contribution to journalAbstractpeer-review


Overuse of short-acting β2-agonist (SABA) inhalers to manage asthma is associated with increased risk of adverse outcomes. Over-the-counter (OTC) SABA availability and automated practitioner provision of up to 12 inhalers/prescription has created the perfect storm for potential SABA overuse in Australia.
Original languageEnglish
Article numberAO01-3
Pages (from-to)3-413
Number of pages1
Issue numberS1
Early online date26 Feb 2023
Publication statusPublished - 26 Feb 2023
EventAPSR 2022: The 26th Congress of the Asian Pacific Society of Respirology - Coex, Seoul, Korea, Republic of
Duration: 17 Nov 202220 Nov 2022
Conference number: 26

Bibliographical note

We would like to acknowledge and thank Steph James, Kiran Dhillon, Sophie Jones, Rob Campbell, Ying Liu, Marion Magee, Ondrej Rejda, Lisa Sugg, and Nicole O'Sullivan for their valuable contributions.


Dive into the research topics of 'Ending the reign of short-acting β2-agonists in Australia?'. Together they form a unique fingerprint.

Cite this